Posted by Michael Wonder on 18 Jul 2023
Roche withdraws type II variation for Gazyvaro
18 July 2023 - The EMA has published the letter from Roche on its website.
Roche Registration GmbH has taken the decision to withdraw the application for a new indication for obinutuzumab as a pre-treatment to reduce the risk of cytokine release syndrome induced by glofitamab.
